Table 1.
Summary of IC50 values for CF10, F10, and 5-FU in select PDA conventional and patient-derived cell lines. p values were calculated utilizing an two-tailed Student’s t-test comparing CF10 to F10 or 5-FU. (†= Previously published; * = p < .05; ** = p < .01; *** = p < .001; **** = p < .0001).
| IC50 (nM) | CF10 | F10 | 5FU |
|---|---|---|---|
| BXPC3 | 3.13 ± 0.74 | 5.22 ± 22.60 (p = .066) | 2603.00 ± 245.27 (****) |
| Increased CF10 potency: | 1.7x | 831x | |
| Capan-1 | 101.80 ± 22.60 | 1357.00 ± 230.70 (***) | 10627.00 ± 817.90 (****) |
| Increased CF10 potency: | 13.3x | 104x | |
| Capan-2 | 131.50 ± 48.50 | 567.50 ± 27.10 (***) | 8193.00 ± 659.60 (****) |
| Increased CF10 potency: | 4.3x | 62.3x | |
| HPAF-II | 333.60 ± 52.00 | 566.30 ± 29.70 (**) | 3557.00 ± 370.20 (***) |
| Increased CF10 potency: | 1.7x | 10.7x | |
| HS 766T | 217.90 ± 38.12 | 480.80 ± 87.10 (**) | 25093.00 ± 4382.00 (***) |
| Increased CF10 potency: | 2.2x | 115x | |
| AsPC-1† | 85.30 ± 4.62 | 1203.00 ± 308.70 (**) | 15820.00 ± 529.90 (****) |
| Increased CF10 potency: | 14.1x | 185x | |
| MIA PaCa-2† | 7.06 ± 2.89 | 25.43 ± 4.00 (**) | 6277.00 ± 426.00 (****) |
| Increased CF10 potency: | 3.6x | 889x | |
| Panc-1† | 46.01 ± 1.19 | 345.10 ± 33.00 (****) | 12340.00 ± 1163.00 (****) |
| Increased CF10 potency: | 7.5x | 268x | |
| 4853-T | 18.08 | 11480(**) | |
| Increased CF10 potency: | 638x | ||
| 7171-T | 32.66 | 31990(**) | |
| Increased CF1- potency: | 1000x | ||
| Combined increased average CF10 potency: | 6.1x | 308x | |
| Correlation vs 5FU | CF10 vs 5FU: R2, 0.03, p value 0.68, not significant. | F10 vs 5FU: R2, 0.11, p value 0.41, not significant. |